Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Contineum Therapeutics (CTNM) over the last 3 years, with Q2 2025 value amounting to $5.6 million.

  • Contineum Therapeutics' Gains from Investment Securities rose 5083283.64% to $5.6 million in Q2 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 6364.93%. This contributed to the annual value of $4.0 million for FY2024, which is 5126.73% up from last year.
  • As of Q2 2025, Contineum Therapeutics' Gains from Investment Securities stood at $5.6 million, which was up 5083283.64% from $200000.0 recorded in Q1 2025.
  • In the past 5 years, Contineum Therapeutics' Gains from Investment Securities ranged from a high of $6.6 million in Q4 2024 and a low of -$11000.0 during Q2 2024
  • For the 3-year period, Contineum Therapeutics' Gains from Investment Securities averaged around $2.3 million, with its median value being $574000.0 (2023).
  • In the last 5 years, Contineum Therapeutics' Gains from Investment Securities soared by 5773726.0% in 2024 and then plummeted by 9306.0% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Gains from Investment Securities (Quarter) stood at $574000.0 in 2023, then skyrocketed by 1042.33% to $6.6 million in 2024, then dropped by 14.89% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q2 2025, $200000.0 for Q1 2025, and $6.6 million during Q4 2024.